Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Charles Ngoh"'
Autor:
Philip Anderson, Joel Yarney, Majid Twahir, Razaq Oyesegun, Andrew Gachii, Clement Edusa, Chukwumere Nwogu, Gitangu Mangutha, Emmanuel Benjamin, Borna Müller, Charles Ngoh
Publikováno v:
BMJ Open, Vol 11, Iss 3 (2021)
Objective To evaluate medical resource utilisation and timeliness of access to specific aspects of a standard care pathway for breast cancer at tertiary centres in sub-Saharan Africa.Design Data were retrospectively abstracted from records of patient
Externí odkaz:
https://doaj.org/article/4dee473c881c46c4a9b7be244ae76bb3
Autor:
Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh, Tim Waterboer
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157957 (2016)
Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify acti
Externí odkaz:
https://doaj.org/article/69c211c7b19144288c202f5e46f52f81
Autor:
Gitangu Mangutha, Borna Müller, Philip W. Anderson, Emmanuel Olatunbosun Benjamin, Razaq Oyesegun, Charles Ngoh, Clement Edusa, Joel Yarney, Chukwumere Nwogu, Majid Twahir, Andrew Gachii
Publikováno v:
BMJ Open
BMJ Open, Vol 11, Iss 3 (2021)
BMJ Open, Vol 11, Iss 3 (2021)
ObjectiveTo evaluate medical resource utilisation and timeliness of access to specific aspects of a standard care pathway for breast cancer at tertiary centres in sub-Saharan Africa.DesignData were retrospectively abstracted from records of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::210727e7666cab5b30ee237905f8417c
http://europepmc.org/articles/PMC7929861
http://europepmc.org/articles/PMC7929861
Autor:
Majid Twahir, Borna Müller, Charles Ngoh, Joel Yarney, Clement Edusa, Andrew Gachii, Gitangu Mangutha, Chukwumere Nwogu, Philip W. Anderson, Rasaaq Adisa Oyesegun, Emmanuel Olatunbosun Benjamin
Publikováno v:
Journal of Clinical Oncology. 37:6562-6562
6562 Background: Breast cancer is the most frequently diagnosed malignancy and the most common cause of cancer-related death in women in Ghana, Kenya, and Nigeria. We evaluated healthcare resource use and financial burden for patients treated at tert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8465cc4220b1007c5f18a5f08053299
https://doi.org/10.1200/jco.2019.37.15_suppl.6562
https://doi.org/10.1200/jco.2019.37.15_suppl.6562
Autor:
Jaafar Bennouna, Stefan Kubicka, Dirk Arnold, Charles Ngoh, Uwe Siebert, Tamlyn Rautenberg, Stefan Walzer
Publikováno v:
Journal of Medical Economics. 17:99-110
Background:Patients with unresectable, metastatic colorectal cancer with wild type Kirsten ras mutational status are eligible for sequential treatments which include monoclonal antibodies as first line (1L), second line (2L), or third line (3L) regim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d6a7296e43a01088bdcd420e4aca125
https://doi.org/10.3111/13696998.2013.864973
https://doi.org/10.3111/13696998.2013.864973
Autor:
Tim Waterboer, Christof Wiesner, Angelo Michele Carella, Mariana Sandoval, P. Kritikou, Charles Ngoh, Erwin De Cock, S. Tao
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 6, p e0157957 (2016)
PLoS ONE, Vol 11, Iss 6, p e0157957 (2016)
Background Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc94b87f80a15696117f346ea9fdb0ef
http://europepmc.org/articles/PMC4928781
http://europepmc.org/articles/PMC4928781
Autor:
Alain Vergnenegre, Dmitry Gultyaev, Javier de Castro Carpeño, Ralph Crott, Martin Kleman, Johanna Lister, Stefan Walzer, Filippo de Marinis, Charles Ngoh, Jie Meng, Christos Chouaid
Publikováno v:
Expert review of anticancer therapy. 15(1)
In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b43d72abcaf0c074be60fdfde268bf6a
https://pubmed.ncbi.nlm.nih.gov/25248391
https://pubmed.ncbi.nlm.nih.gov/25248391
Publikováno v:
Value in Health. 17(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ccdf8a75a1ed8614d2997f6a7373b6a
Autor:
Myung Ah Lee, Young Suk Park, Sang Joon Shin, Seok Jin Park, Johanna Lister, Eui Kyung Lee, Charles Ngoh, Dae Young Zang, Cedric Revil, Nam Su Lee, Eun Jin Bae, Jeong Mi Kwon, Mi Jeong Kang, Mee Hye Park
Publikováno v:
Clinical therapeutics. 34(6)
Background Bevacizumab has been extensively investigated in combination with various standard chemotherapies in the treatment of metastatic colorectal cancer (mCRC). However, a comparison to irinotecan + infusional 5-fluorouracil/leucovorin (FOLFIRI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f831e686aac54ec0b781908b9af532
https://pubmed.ncbi.nlm.nih.gov/22657254
https://pubmed.ncbi.nlm.nih.gov/22657254
Autor:
Johanna Lister, J. de Castro, Christos Chouaid, M. Kleman, Dmitry Gultyaev, Stefan Walzer, Jie Meng, Ralph Crott, A. Vergnenegre, Charles Ngoh, F. De Marinis
Publikováno v:
Value in Health. 17:A70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::616557d049bd865daedb22e8d94aa9e3
https://doi.org/10.1016/j.jval.2014.03.408
https://doi.org/10.1016/j.jval.2014.03.408